ag-120
IDH1 Mutation
Massachusetts General HospitalPhase 2Active
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the IDH1 Mutation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Venetoclax Justin Watts, MD | Phase 2 | B |
Azacitidine Shen yang | Phase 2 | B |
Nivolumab Jason J. Luke, MD | Phase 2 | B |
Cytosin-Arabinosid Shen yang | Phase 2 | CCC |
Olutasidenib Timothy Pardee | Phase 2 | CCC |
Daunorubicin Shen yang | Phase 2 | CCC |
Pamiparib Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1/2 | CCC |
Same molecule, other indications
ag-120 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →